Status:
COMPLETED
Hormone Therapy on Serum Ischemia Modified Albumin in Menopausal Women
Lead Sponsor:
Karadeniz Technical University
Conditions:
Hormone Therapy Induced Morphologic Change
Surgical Menopause
Eligibility:
FEMALE
45-55 years
Brief Summary
Women suffer from cardiovascular diseases 10 years later than men, therefore female sex has been considered as a 'protective factor'. However, the risk of cardiovascular disease in women increases rap...
Eligibility Criteria
Inclusion
- accepting consent to participate in the trial and signing the form
- Surgical menopausal women aged 45-55 (having TAH + BSO for benign reasons)
- Presence of vasomotor or menopausal symptoms (moderate to severe);
- no systemic disease or infectious disease in the past 2 weeks
- Not taking any other hormone therapy or medication until postoperative 6th week;
- no contraindications for hormone therapy in routine menopause evaluation;
- Willingness to take hormone therapy
- No smoking.
Exclusion
- Any systemic disease presence
- Smoking
- Contraindications for hormone therapy
- Failure to follow-up
- Inability to complete three months of hormone therapy
- quitting hormone therapy for other medical reasons during hormone therapy
- Cases reported as preinvasive and invasive genital tumors as a result of TAH + BSO
- Cases reported as suspicious findings in the mammography report
Key Trial Info
Start Date :
July 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 20 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04424108
Start Date
July 1 2009
End Date
May 20 2010
Last Update
June 9 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.